[Seite 54↓]

Literaturverzeichnis

Albegger, K.; Hauser-Kronberger, C. E.; Saria, A.; Graf, A. H.; Bernatzky, G. and Hacker, G. W. (1991): Regulatory peptides and general neuroendocrine markers in human nasal mucosa, soft palate and larynx, Acta Otolaryngol, (vol. 111), No. 2, pp.373-8.

Altiere, R. J. and Diamond, L. (1984): Comparison of vasoactive intestinal peptide and isoproterenol relaxant effects in isolated cat airways, J Appl Physiol, (vol. 56), No. 4, pp.986-92.

Altiere, R. J.; Kung, M. and Diamond, L. (1984): Comparative effects of inhaled isoproterenol and vasoactive intestinal peptide on histamine-induced bronchoconstriction in human subjects, Chest, (vol. 86), No. 1, pp.153-4.

Arck, P. C.; Handjiski, B.; Hagen, E.; Joachim, R.; Klapp, B. F. and Paus, R. (2001): Indications for a 'brain-hair follicle axis (BHA)': inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P, FASEB J, (vol. 15), No. 13, pp.2536-8.

Babu, K. S. and Salvi, S. S. (2000): Aspirin and asthma, Chest, (vol. 118), No. 5, pp.1470-6..

Baraniuk, J. N. (2001): Neurogenic mechanisms in rhinosinusitis, Curr Allergy Asthma Rep, (vol. 1), No. 3, pp.252-61.

Baraniuk, J. N.; Castellino, S.; Lundgren, J. D.; Goff, J.; Mullol, J.; Merida, M.; Shelhamer, J. H. and Kaliner, M. A. (1990): Neuropeptide Y (NPY) in human nasal mucosa, Am J Respir Cell Mol Biol, (vol. 3), No. 2, pp.165-73.


[Seite 55↓]

Baraniuk, J. N.; Lundgren, J. D.; Goff, J.; Mullol, J.; Castellino, S.; Merida, M.; Shelhamer, J. H. and Kaliner, M. A. (1990): Calcitonin gene-related peptide in human nasal mucosa, Am J Physiol, (vol. 258), No. 2 Pt 1, pp.L81-8.

Baraniuk, J. N.; Lundgren, J. D.; Okayama, M.; Mullol, J.; Merida, M.; Shelhamer, J. H. and Kaliner, M. A. (1990): Vasoactive intestinal peptide in human nasal mucosa, J Clin Invest, (vol. 86), No. 3, pp.825-31.

Barnes, P. J.; Cadieux, A.; Carstairs, J. R.; Greenberg, B.; Polak, J. M. and Rhoden, K. (1986): Vasoactive intestinal peptide in bovine pulmonary artery: localisation, function and receptor autoradiography, Br J Pharmacol, (vol. 89), No. 1, pp.157-62.

Barnes, P. J.; Chung, K. F. and Page, C. P. (1998): Inflammatory mediators of asthma: an update, Pharmacol Rev, (vol. 50), No. 4, pp.515-96.

Bayliss, W. M. (1901): On the origin from the spinal cord of the vaso-dilator fibres of the hind.limband on the nature of these fibres, J Physiol (Lond), (vol. 26), pp.173-209.

Bedoui, S.; Kawamura, N.; Straub, R. H.; Pabst, R.; Yamamura, T. and von Horsten, S. (2003): Relevance of neuropeptide Y for the neuroimmune crosstalk, J Neuroimmunol, (vol. 134), No. 1-2, pp.1-11.

Belvisi, M. G. (2003): Sensory nerves and airway inflammation: role of A delta and C-fibres, Pulm Pharmacol Ther, (vol. 16), No. 1, pp.1-7.

Bienenstock, J.; MacQueen, G.; Sestini, P.; Marshall, J. S.; Stead, R. H. and Perdue, M. H. (1991): Mast cell/nerve interactions in vitro and in vivo, Am Rev Respir Dis, (vol. 143), No. 3 Pt 2, pp.S55-8.

Blackley, C. H. B. (1873): Experimental researches on the causes and nature of Catarrhus aestivus (hay-fever or hay-asthma), Baillliére, Tindall & Cox, London.


[Seite 56↓]

Bolin, D. R.; Cottrell, J.; Garippa, R.; O'Neill, N.; Simko, B. and O'Donnell, M. (1993): Structure-activity studies of vasoactive intestinal peptide (VIP): cyclic disulfide analogs, Int J Pept Protein Res, (vol. 41), No. 2, pp.124-32.

Boomsma, J. D. and Said, S. I. (1992): The role of neuropeptides in asthma, Chest, (vol. 101), No. 6 Suppl, pp.389S-392S.

Botchkarev, V. A.; Botchkareva, N. V.; Lommatzsch, M.; Peters, E. M.; Lewin, G. R.; Subramaniam, A.; Braun, A.; Renz, H. and Paus, R. (1998): BDNF overexpression induces differential increases among subsets of sympathetic innervation in murine back skin, Eur J Neurosci, (vol. 10), No. 10, pp.3276-83.

Botchkarev, V. A.; Welker, P.; Albers, K. M.; Botchkareva, N. V.; Metz, M.; Lewin, G. R.; Bulfone-Paus, S.; Peters, E. M.; Lindner, G. and Paus, R. (1998): A new role for neurotrophin-3: involvement in the regulation of hair follicle regression (catagen), Am J Pathol, (vol. 153), No. 3, pp.785-99.

Bowden, J. J. and Gibbins, I. L. (1992): Vasoactive intestinal peptide and neuropeptide Y coexist in non-noradrenergic sympathetic neurons to guinea pig trachea, J Auton Nerv Syst, (vol. 38), No. 1, pp.1-19.

Bundgaard, A.; Enehjelm, S. D. and Aggestrup, S. (1983): Pretreatment of exercise-induced asthma with inhaled vasoactive intestinal peptide (VIP), Eur J Respir Dis Suppl, (vol. 128), No. Pt 2, pp.427-9.

Busto, R.; Prieto, J. C.; Bodega, G.; Zapatero, J. and Carrero, I. (2000): Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung, Peptides, (vol. 21), No. 2, pp.265-9.


[Seite 57↓]

Canning, B. J.; Fischer, A. and Undem, B. J. (1998): Pharmacological analysis of the tachykinin receptors that mediate activation of nonadrenergic, noncholinergic relaxant nerves that innervate guinea pig trachealis, J Pharmacol Exp Ther, (vol. 284), No. 1, pp.370-7.

Carstairs, J. R. and Barnes, P. J. (1986): Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung, J Pharmacol Exp Ther, (vol. 239), No. 1, pp.249-55.

Chang, M. M.; Leeman, S. E. and Niall, H. D. (1971): Amino-acid sequence of substance P, Nat New Biol, (vol. 232), No. 29, pp.86-7.

Chung, K. F. and Barnes, P. J. (1999): Cytokines in asthma, Thorax, (vol. 54), No. 9, pp.825-57.

Ciccarelli, E.; Vilardaga, J. P.; De Neef, P.; Di Paolo, E.; Waelbroeck, M.; Bollen, A. and Robberecht, P. (1994): Properties of the VIP-PACAP type II receptor stably expressed in CHO cells, Regul Pept, (vol. 54), No. 2-3, pp.397-407.

Coles, S. J.; Said, S. I. and Reid, L. M. (1981): Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro, Am Rev Respir Dis, (vol. 124), No. 5, pp.531-6.

Couvineau, A.; Rouyer-Fessard, C.; Darmoul, D.; Maoret, J. J.; Carrero, I.; Ogier-Denis, E. and Laburthe, M. (1994): Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains, Biochem Biophys Res Commun, (vol. 200), No. 2, pp.769-76.

Couvineau, A.; Rouyer-Fessard, C.; Maoret, J. J.; Gaudin, P.; Nicole, P. and Laburthe, M. (1996): Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide, J Biol Chem, (vol. 271), No. 22, pp.12795-800.


[Seite 58↓]

Cox, C. P.; Lerner, M. R.; Wells, J. J. and Said, S. I. (1983): Inhaled vasoactive intestinal peptide (VIP) prevents bronchoconstriction induced by inhaled histamine, Am Rev Respir Dis, (vol. 127), p.A249.

Delgado, M. (2002): Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia, Biochem Biophys Res Commun, (vol. 297), No. 5, pp.1181-5.

Delgado, M. (2003): Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression, J Biol Chem, (vol. 278), No. 30, pp.27620-9.

Delgado, M.; Abad, C.; Martinez, C.; Leceta, J. and Gomariz, R. P. (2001): Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease, Nat Med, (vol. 7), No. 5, pp.563-8.

Delgado, M. and Ganea, D. (2001): Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3, J Immunol, (vol. 166), No. 2, pp.1028-40.

Dessi, P.; Sambuc, R.; Moulin, G.; Ledoray, V. and Cannoni, M. (1994): Effect of heavy smoking on nasal resistance, Acta Otolaryngol, (vol. 114), No. 3, pp.305-10.

Dey, R. D.; Shannon, W. A., Jr. and Said, S. I. (1981): Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects, Cell Tissue Res, (vol. 220), No. 2, pp.231-8.


[Seite 59↓]

Diamond, L.; Szarek, J. L.; Gillespie, M. N. and Altiere, R. J. (1983): In vivo bronchodilator activity of vasoactive intestinal peptide in the cat, Am Rev Respir Dis, (vol. 128), No. 5, pp.827-32.

Eedy, D. J.; Shaw, C.; Johnston, C. F. and Buchanan, K. D. (1994): The regional distribution of neuropeptides in human skin as assessed by radioimmunoassay and high-performance liquid chromatography, Clin Exp Dermatol, (vol. 19), No. 6, pp.463-72.

Eynott, P. R.; Groneberg, D. A.; Caramori, G.; Adcock, I. M.; Donnelly, L. E.; Kharitonov, S.; Barnes, P. J. and Chung, K. F. (2002): Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness, Eur J Pharmacol, (vol. 452), No. 1, pp.123-33.

Eynott, P. R.; Paavolainen, N.; Groneberg, D. A.; Noble, A.; Salmon, M.; Nath, P.; Leung, S. Y. and Chung, K. F. (2003): Role of nitric oxide in chronic allergen-induced airway cell proliferation and inflammation, J Pharmacol Exp Ther, (vol. 304), No. 1, pp.22-9.

Fischer, A.; Folkerts, G.; Geppetti, P. and Groneberg, D. A. (2002): Mediators of asthma: nitric oxide, Pulm Pharmacol Ther, (vol. 15), No. 2, pp.73-81.

Fischer, A. and Hoffmann, B. (1996): Nitric oxide synthase in neurons and nerve fibers of lower airways and in vagal sensory ganglia of man. Correlation with neuropeptides, Am J Respir Crit Care Med, (vol. 154), No. 1, pp.209-16..

Fischer, A.; Kummer, W.; Couraud, J. Y.; Adler, D.; Branscheid, D. and Heym, C. (1992): Immunohistochemical localization of receptors for vasoactive intestinal peptide and substance P in human trachea, Lab Invest, (vol. 67), No. 3, pp.387-93.


[Seite 60↓]

Fischer, A.; McGregor, G. P.; Saria, A.; Philippin, B. and Kummer, W. (1996): Induction of tachykinin gene and peptide expression in guinea pig nodose primary afferent neurons by allergic airway inflammation, J Clin Invest, (vol. 98), No. 10, pp.2284-91.

Fischer, A. R.; Rosenberg, M. A.; Lilly, C. M.; Callery, J. C.; Rubin, P.; Cohn, J.; White, M. V.; Igarashi, Y.; Kaliner, M. A. and Drazen, J. M. (1994): Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma, J Allergy Clin Immunol, (vol. 94), No. 6 Pt 1, pp.1046-56.

Fischer, T. C.; Dinh, Q. T.; Peiser, C.; Loser, C.; Fischer, A. and Groneberg, D. A. (2002): Simultaneous detection of receptor mRNA and ligand protein in human skin tissues, J Cutan Pathol, (vol. 29), No. 2, pp.65-71.

Foord, S. M. and Marshall, F. H. (1999): RAMPs: accessory proteins for seven transmembrane domain receptors, Trends Pharmacol Sci, (vol. 20), No. 5, pp.184-7.

Galli, E.; Cicconi, R.; Rossi, P.; Casati, A.; Brunetti, E. and Mancino, G. (2003): Atopic dermatitis: molecular mechanisms, clinical aspects and new therapeutical approaches, Curr Mol Med, (vol. 3), No. 2, pp.127-38.

Goetzl, E. J.; Voice, J. K.; Shen, S.; Dorsam, G.; Kong, Y.; West, K. M.; Morrison, C. F. and Harmar, A. J. (2001): Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide, Proc Natl Acad Sci U S A, (vol. 98), No. 24, pp.13854-9.

Gomariz, R. P.; Martinez, C.; Abad, C.; Leceta, J. and Delgado, M. (2001): Immunology of VIP: a review and therapeutical perspectives, Curr Pharm Des, (vol. 7), No. 2, pp.89-111.

Gourlet, P.; De Neef, P.; Cnudde, J.; Waelbroeck, M. and Robberecht, P. (1997): In vitro properties of a high affinity selective antagonist of the VIP1 receptor, Peptides, (vol. 18), No. 10, pp.1555-60.


[Seite 61↓]

Gourlet, P.; Vandermeers, A.; Vertongen, P.; Rathe, J.; De Neef, P.; Cnudde, J.; Waelbroeck, M. and Robberecht, P. (1997): Development of high affinity selective VIP1 receptor agonists, Peptides, (vol. 18), No. 10, pp.1539-45.

Gourlet, P.; Vertongen, P.; Vandermeers, A.; Vandermeers-Piret, M. C.; Rathe, J.; De Neef, P.; Waelbroeck, M. and Robberecht, P. (1997): The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass, Peptides, (vol. 18), No. 3, pp.403-8.

Gozes, I. and Brenneman, D. E. (1989): VIP: molecular biology and neurobiological function, Mol Neurobiol, (vol. 3), No. 4, pp.201-36.

Gozes, I.; Fridkin, M. and Brenneman, D. E. (1995): A VIP hybrid antagonist: from developmental neurobiology to clinical applications, Cell Mol Neurobiol, (vol. 15), No. 6, pp.675-87.

Gozes, I.; Nakai, H.; Byers, M.; Avidor, R.; Weinstein, Y.; Shani, Y. and Shows, T. B. (1987): Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24, Somat Cell Mol Genet, (vol. 13), No. 4, pp.305-13.

Greenberg, B.; Rhoden, K. and Barnes, P. J. (1987): Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries, Blood Vessels, (vol. 24), No. 1-2, pp.45-50.

Groneberg, D. A. (2003): Expression, Lokalisation und funktionelle Aspekte des Peptidtransporters PEPT2 im gesunden Atemtrakt und bei Mukoviszidose, Pneumologie, (vol. 57), No. 2, pp.104-5.

Groneberg, D. A.; Doring, F.; Nickolaus, M.; Daniel, H. and Fischer, A. (2001): Expression of PEPT2 peptide transporter mRNA and protein in glial cells of rat dorsal root ganglia, Neurosci Lett, (vol. 304), No. 3, pp.181-4.


[Seite 62↓]

Groneberg, D. A.; Eynott, P. R.; Doring, F.; Thai Dinh, Q.; Oates, T.; Barnes, P. J.; Chung, K. F.; Daniel, H. and Fischer, A. (2002): Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung, Thorax, (vol. 57), No. 1, pp.55-60.

Groneberg, D. A.; Eynott, P. R.; Lim, S.; Oates, T.; Wu, R.; Carlstedt, I.; Roberts, P.; McCann, B.; Nicholson, A. G.; Harrison, B. D. and Chung, K. F. (2002): Expression of respiratory mucins in fatal status asthmaticus and mild asthma, Histopathology, (vol. 40), No. 4, pp.367-73.

Groneberg, D. A.; Eynott, P. R.; Oates, T.; Lim, S.; Wu, R.; Carlstedt, I.; Nicholson, A. G. and Chung, K. F. (2002): Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung, Respir Med, (vol. 96), No. 2, pp.81-6.

Groneberg, D. A. and Fischer, A. (2001): Endogenous opioids as mediators of asthma, Pulm Pharmacol Ther, (vol. 14), No. 5, pp.383-9.

Groneberg, D. A.; Nickolaus, M.; Springer, J.; Doring, F.; Daniel, H. and Fischer, A. (2001): Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake, Am J Pathol, (vol. 158), No. 2, pp.707-14.

Groneberg, D. A.; Peiser, C.; Dinh, Q. T.; Matthias, J.; Eynott, P. R.; Heppt, W.; Carlstedt, I.; Witt, C.; Fischer, A. and Chung, K. F. (2003): Distribution of respiratory mucin proteins in human nasal mucosa, Laryngoscope, (vol. 113), No. 3, pp.520-4.

Groneberg, D. A.; Springer, J. and Fischer, A. (2001): Vasoactive intestinal polypeptide as mediator of asthma, Pulm Pharmacol Ther, (vol. 14), No. 5, pp.391-401.

Groneberg, D. A.; Wagner, U. and Chung, K. F. (2004): Mucus and fatal asthma, Am J Med, (vol. 116), pp.66-67.


[Seite 63↓]

Hachisu, M.; Hiranuma, T.; Tani, S. and Iizuka, T. (1991): Enzymatic degradation of helodermin and vasoactive intestinal polypeptide, J Pharmacobiodyn, (vol. 14), No. 3, pp.126-31.

Haegerstrand, A.; Jonzon, B.; Dalsgaard, C. J. and Nilsson, J. (1989): Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes, Proc Natl Acad Sci U S A, (vol. 86), No. 15, pp.5993-6.

Hamasaki, Y.; Mojarad, M. and Said, S. I. (1983): Relaxant action of VIP on cat pulmonary artery: comparison with acetylcholine, isoproterenol, and PGE1, J Appl Physiol, (vol. 54), No. 6, pp.1607-11.

Hamasaki, Y.; Saga, T.; Mojarad, M. and Said, S. I. (1983): Vasoactive intestinal peptide counteracts leukotriene D4-induced contractions of guinea pig trachea, lung, and pulmonary artery, Trans Assoc Am Physicians, (vol. 96), pp.406-11.

Hand, J. M.; Laravuso, R. B. and Will, J. A. (1984): Relaxation of isolated guinea pig trachea, bronchi and pulmonary arteries produced by vasoactive intestinal peptide (VIP), Eur J Pharmacol, (vol. 98), No. 2, pp.279-84.

Harmar, A. J.; Arimura, A.; Gozes, I.; Journot, L.; Laburthe, M.; Pisegna, J. R.; Rawlings, S. R.; Robberecht, P.; Said, S. I.; Sreedharan, S. P.; Wank, S. A. and Waschek, J. A. (1998): International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide, Pharmacol Rev, (vol. 50), No. 2, pp.265-70.

Hisanaga, K.; Sagar, S. M.; Koistinaho, J.; Hicks, K. J. and Sharp, F. R. (1993): VIP-induced stellation and immediate early gene expression in astrocytes: effects of dexamethasone, Neurosci Lett, (vol. 156), No. 1-2, pp.57-60.


[Seite 64↓]

Howarth, P. H. (1997): Mediators of nasal blockage in allergic rhinitis, Allergy, (vol. 52), No. 40 Suppl, pp.12-8.

Hua, X. Y.; Theodorsson-Norheim, E.; Brodin, E.; Lundberg, J. M. and Hokfelt, T. (1985): Multiple tachykinins (neurokinin A, neuropeptide K and substance P) in capsaicin-sensitive sensory neurons in the guinea-pig, Regul Pept, (vol. 13), No. 1, pp.1-19.

Inagaki, N.; Yoshida, H.; Mizuta, M.; Mizuno, N.; Fujii, Y.; Gonoi, T.; Miyazaki, J. and Seino, S. (1994): Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells, Proc Natl Acad Sci U S A, (vol. 91), No. 7, pp.2679-83.

Ishihara, T.; Shigemoto, R.; Mori, K.; Takahashi, K. and Nagata, S. (1992): Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide, Neuron, (vol. 8), No. 4, pp.811-9.

Ito, O. and Tachibana, S. (1991): Vasoactive intestinal polypeptide precursors have highly potent bronchodilatory activity, Peptides, (vol. 12), No. 1, pp.131-7.

Jancso, N.; Jancso-Gabor, A. and Szolcsanyi, J. (1967): Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin, Br J Pharmacol, (vol. 31), No. 1, pp.138-51.

Jones, A. S. (1988): Non-allergic perennial rhinitis, Biomed Pharmacother, (vol. 42), No. 8, pp.499-503..

Jones, A. S. (1997): Autonomic reflexes and non-allergic rhinitis, Allergy, (vol. 52), No. 36 Suppl, pp.14-9..


[Seite 65↓]

Joos, G. F.; De Swert, K. O. and Pauwels, R. A. (2001): Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists, Eur J Pharmacol, (vol. 429), No. 1-3, pp.239-50.

Joos, G. F.; Germonpre, P. R. and Pauwels, R. A. (2000): Role of tachykinins in asthma, Allergy, (vol. 55), No. 4, pp.321-37.

Joos, G. F. and Pauwels, R. A. (2001): Tachykinin receptor antagonists: potential in airways diseases, Curr Opin Pharmacol, (vol. 1), No. 3, pp.235-41.

Kallos, P. and Kallos, L. (1984): Experimental asthma in guinea-pigs revisited, Int Arch Allergy Appl Immunol, (vol. 73), pp.77-85.

Kapas, S.; Catt, K. J. and Clark, A. J. (1995): Cloning and expression of cDNA encoding a rat adrenomedullin receptor, J Biol Chem, (vol. 270), No. 43, pp.25344-7.

Keith, I. M. (2000): The role of endogenous lung neuropeptides in regulation of the pulmonary circulation, Physiol Res, (vol. 49), No. 5, pp.519-37.

Kemp, A. S. (2003): Cost of illness of atopic dermatitis in children: a societal perspective, Pharmacoeconomics, (vol. 21), No. 2, pp.105-13.

Kennedy, S. P.; Sun, D.; Oleynek, J. J.; Hoth, C. F.; Kong, J. and Hill, R. J. (1998): Expression of the rat adrenomedullin receptor or a putative human adrenomedullin receptor does not correlate with adrenomedullin binding or functional response, Biochem Biophys Res Commun, (vol. 244), No. 3, pp.832-7.

Kotani, H.; Hoshimaru, M.; Nawa, H. and Nakanishi, S. (1986): Structure and gene organization of bovine neuromedin K precursor, Proc Natl Acad Sci U S A, (vol. 83), No. 18, pp.7074-8.


[Seite 66↓]

Kowalski, M. L. (2000): Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different?, Thorax, (vol. 55), No. Suppl 2, pp.S84-6..

Kraneveld, A. D. and Nijkamp, F. P. (2001): Tachykinins and neuro-immune interactions in asthma, Int Immunopharmacol, (vol. 1), No. 9-10, pp.1629-50.

Kummer, W.; Fischer, A.; Kurkowski, R. and Heym, C. (1992): The sensory and sympathetic innervation of guinea-pig lung and trachea as studied by retrograde neuronal tracing and double-labelling immunohistochemistry, Neuroscience, (vol. 49), No. 3, pp.715-37.

Kusakabe, T.; Hirakawa, H.; Matsuda, H.; Kawakami, T.; Takenaka, T. and Hayashida, Y. (2003): Peptidergic innervation in the rat carotid body after 2, 4, and 8 weeks of hypocapnic hypoxic exposure, Histol Histopathol, (vol. 18), No. 2, pp.409-18.

Lacroix, J. S.; Correia, F.; Fathi, M. and Grouzmann, E. (1997): Post-exercise nasal vasoconstriction and hyporeactivity: possible involvement of neuropeptide Y, Acta Otolaryngol, (vol. 117), No. 4, pp.609-13.

Laitinen, L. A.; Laitinen, A.; Salonen, R. O. and Widdicombe, J. G. (1987): Vascular actions of airway neuropeptides, Am Rev Respir Dis, (vol. 136), No. 6 Pt 2, pp.S59-64.

Leung, D. Y. and Bieber, T. (2003): Atopic dermatitis, Lancet, (vol. 361), No. 9352, pp.151-60.

Leung, S. Y.; Eynott, P. R.; Nath, P.; Adcock, I. M. and Chung, K. F. (2002): Effects of Selective C-JUN NH2-Terminal Kinase Inhibition in a Sensitized Brown-Norway Rat Model of Chronic Allergic Asthma, Am J Respir Crit Care Med, (vol. 167), No. 7, p.A344.


[Seite 67↓]

Lilly, C. M.; Drazen, J. M. and Shore, S. A. (1993): Peptidase modulation of airway effects of neuropeptides, Proc Soc Exp Biol Med, (vol. 203), No. 4, pp.388-404.

Linden, A. (1996): NANC neural control of airway smooth muscle tone, Gen Pharmacol, (vol. 27), No. 7, pp.1109-21.

Linden, A.; Hansson, L.; Andersson, A.; Palmqvist, M.; Arvidsson, P.; Lofdahl, C. G.; Larsson, P. and Lotvall, J. (2003): Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma, Thorax, (vol. 58), No. 3, pp.217-21.

Lund, V. (1998): Allergic rhinitis--making the correct diagnosis, Clin Exp Allergy, (vol. 28), No. Suppl 6, pp.25-8..

Lundberg, J. M.; Anggard, A.; Emson, P.; Fahrenkrug, J. and Hokfelt, T. (1981): Vasoactive intestinal polypeptide and cholinergic mechanisms in cat nasal mucosa: studies on choline acetyltransferase and release of vasoactive intestinal polypeptide, Proc Natl Acad Sci U S A, (vol. 78), No. 8, pp.5255-9.

Lundberg, J. M.; Fahrenkrug, J.; Hokfelt, T.; Martling, C. R.; Larsson, O.; Tatemoto, K. and Anggard, A. (1984): Co-existence of peptide HI (PHI) and VIP in nerves regulating blood flow and bronchial smooth muscle tone in various mammals including man, Peptides, (vol. 5), No. 3, pp.593-606.

Lundberg, J. M.; Franco-Cereceda, A.; Hua, X.; Hokfelt, T. and Fischer, J. A. (1985): Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin, Eur J Pharmacol, (vol. 108), No. 3, pp.315-9.


[Seite 68↓]

Lundberg, J. M.; Hokfelt, T.; Martling, C. R.; Saria, A. and Cuello, C. (1984): Substance P-immunoreactive sensory nerves in the lower respiratory tract of various mammals including man, Cell Tissue Res, (vol. 235), No. 2, pp.251-61.

Lung, M. A. and Widdicombe, J. G. (1987): Lung reflexes and nasal vascular resistance in the anaesthetized dog, J Physiol (Lond), (vol. 386), pp.465-74.

Lutz, E. M.; Sheward, W. J.; West, K. M.; Morrow, J. A.; Fink, G. and Harmar, A. J. (1993): The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide, FEBS Lett, (vol. 334), No. 1, pp.3-8.

Maggi, C. A. (1995): The mammalian tachykinin receptors, Gen Pharmacol, (vol. 26), No. 5, pp.911-44.

Maggi, C. A. (1996): Tachykinins in the autonomic nervous system, Pharmacol Res, (vol. 33), No. 3, pp.161-70.

Maggi, C. A.; Giachetti, A.; Dey, R. D. and Said, S. I. (1995): Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins, Physiol Rev, (vol. 75), No. 2, pp.277-322.

Matran, R.; Alving, K.; Martling, C. R.; Lacroix, J. S. and Lundberg, J. M. (1989): Effects of neuropeptides and capsaicin on tracheobronchial blood flow of the pig, Acta Physiol Scand, (vol. 135), No. 3, pp.335-42.

Merten, M. D.; Kammouni, W.; Renaud, W.; Birg, F.; Mattei, M. G. and Figarella, C. (1996): A transformed human tracheal gland cell line, MM-39, that retains serous secretory functions, Am J Respir Cell Mol Biol, (vol. 15), No. 4, pp.520-8.

Metcalfe, D. D.; Baram, D. and Mekori, Y. A. (1997): Mast cells, Physiol Rev, (vol. 77), No. 4, pp.1033-79.

Mikaelian, A. J. (1989): Vasomotor rhinitis, Ear Nose Throat J, (vol. 68), No. 3, pp.207-10, 213-8.


[Seite 69↓]

Morice, A.; Unwin, R. J. and Sever, P. S. (1983): Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects, Lancet, (vol. 2), No. 8361, pp.1225-7.

Mulderry, P. K. and Dobson, S. P. (1996): Regulation of VIP and other neuropeptides by c-Jun in sensory neurons: implications for the neuropeptide response to axotomy, Eur J Neurosci, (vol. 8), No. 12, pp.2479-91.

Nandiwada, P. A.; Kadowitz, P. J.; Said, S. I.; Mojarad, M. and Hyman, A. L. (1985): Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat, J Appl Physiol, (vol. 58), No. 5, pp.1723-8.

Nathanson, I.; Widdicombe, J. H. and Barnes, P. J. (1983): Effect of vasoactive intestinal peptide on ion transport across dog tracheal epithelium, J Appl Physiol, (vol. 55), No. 6, pp.1844-8.

Nawa, H.; Kotani, H. and Nakanishi, S. (1984): Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing, Nature, (vol. 312), No. 5996, pp.729-34.

Obara, H.; Kusunoki, M.; Mori, M.; Mikawa, K. and Iwai, S. (1989): The effects of various peptides on the isolated pulmonary artery, Peptides, (vol. 10), No. 1, pp.241-3.

O'Donnell, M.; Garippa, R. J.; Rinaldi, N.; Selig, W. M.; Simko, B.; Renzetti, L.; Tannu, S. A.; Wasserman, M. A.; Welton, A. and Bolin, D. R. (1994): Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies, J Pharmacol Exp Ther, (vol. 270), No. 3, pp.1282-8.


[Seite 70↓]

O'Donnell, M.; Garippa, R. J.; Rinaldi, N.; Selig, W. M.; Tocker, J. E.; Tannu, S. A.; Wasserman, M. A.; Welton, A. and Bolin, D. R. (1994): Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis, J Pharmacol Exp Ther, (vol. 270), No. 3, pp.1289-94.

Palmer, J. B.; Cuss, F. M. and Barnes, P. J. (1986): VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways, J Appl Physiol, (vol. 61), No. 4, pp.1322-8.

Peatfield, A. C.; Barnes, P. J.; Bratcher, C.; Nadel, J. A. and Davis, B. (1983): Vasoactive intestinal peptide stimulates tracheal submucosal gland secretion in ferret, Am Rev Respir Dis, (vol. 128), No. 1, pp.89-93.

Peiser, C.; Springer, J.; Groneberg, D. A.; McGregor, G. P.; Fischer, A. and Lang, R. E. (2002): Leptin receptor expression in nodose ganglion cells projecting to the rat gastric fundus, Neurosci Lett, (vol. 320), No. 1-2, pp.41-4.

Rawlings, S. R.; Piuz, I.; Schlegel, W.; Bockaert, J. and Journot, L. (1995): Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs, Endocrinology, (vol. 136), No. 5, pp.2088-98.

Richardson, J. D. and Vasko, M. R. (2002): Cellular mechanisms of neurogenic inflammation, J Pharmacol Exp Ther, (vol. 302), No. 3, pp.839-45.

Richardson, P. S. and Webber, S. E. (1987): The control of mucous secretion in the airways by peptidergic mechanisms, Am Rev Respir Dis, (vol. 136), No. 6 Pt 2, pp.S72-6.

Saga, T. and Said, S. I. (1984): Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma, Trans Assoc Am Physicians, (vol. 97), pp.304-10.


[Seite 71↓]

Said, S. I. and Mutt, V. (1969): A peptide fraction from lung tissue with prolonged peripheral vasodilator activity, Scand J Clin Lab Invest Suppl, (vol. 107), pp.51-6.

Said, S. I. and Mutt, V. (1970): Polypeptide with broad biological activity: isolation from small intestine, Science, (vol. 169), No. 951, pp.1217-8.

Said, S. I. and Mutt, V. (1970): Potent peripheral and splanchnic vasodilator peptide from normal gut, Nature, (vol. 225), No. 235, pp.863-4.

Sakai, N.; Tamaoki, J.; Kobayashi, K.; Kanemura, T.; Isono, K.; Takeyama, K.; Takeuchi, S. and Takizawa, T. (1991): Vasoactive intestinal peptide stimulates ciliary motility in rabbit tracheal epithelium: modulation by neutral endopeptidase, Regul Pept, (vol. 34), No. 1, pp.33-41.

Schmidt, D. T.; Ruhlmann, E.; Waldeck, B.; Branscheid, D.; Luts, A.; Sundler, F. and Rabe, K. F. (2001): The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery, Naunyn Schmiedebergs Arch Pharmacol, (vol. 364), No. 4, pp.314-20.

Scholzen, T.; Armstrong, C. A.; Bunnett, N. W.; Luger, T. A.; Olerud, J. E. and Ansel, J. C. (1998): Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems, Exp Dermatol, (vol. 7), No. 2-3, pp.81-96.

Sexton, P. M.; Albiston, A.; Morfis, M. and Tilakaratne, N. (2001): Receptor activity modifying proteins, Cell Signal, (vol. 13), No. 2, pp.73-83.

Sharaf, H., Said, S. I. (1993): Tracheal relaxant response to vasoactive intestinal peptide (VIP): influence of airway epithelium and peptidases (abstract), FASEB J, (vol. 7), p.A686.


[Seite 72↓]

Shimura, S.; Sasaki, T.; Ikeda, K.; Sasaki, H. and Takishima, T. (1988): VIP augments cholinergic-induced glycoconjugate secretion in tracheal submucosal glands, J Appl Physiol, (vol. 65), No. 6, pp.2537-44.

Springer, J.; Geppetti, P.; Fischer, A. and Groneberg, D. A. (2003): Calcitonin gene-related peptide as inflammatory mediator, Pulm Pharmacol Ther, (vol. 16), No. 3, pp.121-30.

Sreedharan, S. P.; Patel, D. R.; Huang, J. X. and Goetzl, E. J. (1993): Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor, Biochem Biophys Res Commun, (vol. 193), No. 2, pp.546-53.

Svoboda, M.; Tastenoy, M.; Van Rampelbergh, J.; Goossens, J. F.; De Neef, P.; Waelbroeck, M. and Robberecht, P. (1994): Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts, Biochem Biophys Res Commun, (vol. 205), No. 3, pp.1617-24.

Szczeklik, A. and Stevenson, D. D. (1999): Aspirin-induced asthma: advances in pathogenesis and management, J Allergy Clin Immunol, (vol. 104), No. 1, pp.5-13..

Tai, C. F. and Baraniuk, J. N. (2002): Upper airway neurogenic mechanisms, Curr Opin Allergy Clin Immunol, (vol. 2), No. 1, pp.11-9.

Tainio, H. (1987): Cytochemical localization of VIP-stimulated adenylate cyclase activity in human sweat glands, Dev Biol, (vol. 123), No. 1, pp.179-90.

Takeda, N.; Kalubi, B.; Abe, Y.; Irifune, M.; Ogino, S. and Matsunaga, T. (1993): Neurogenic inflammation in nasal allergy: histochemical and pharmacological studies in guinea pigs. A review, Acta Otolaryngol Suppl, (vol. 501), pp.21-4.

Togias, A. (2003): Rhinitis and asthma: evidence for respiratory system integration, J Allergy Clin Immunol, (vol. 111), No. 6, pp.1171-83.


[Seite 73↓]

Tregear, G. W.; Niall, H. D.; Potts, J. T., Jr.; Leeman, S. E. and Chang, M. M. (1971): Synthesis of substance P, Nat New Biol, (vol. 232), No. 29, pp.87-9.

Usdin, T. B.; Bonner, T. I. and Mezey, E. (1994): Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions, Endocrinology, (vol. 135), No. 6, pp.2662-80.

van der Velden, V. H. and Hulsmann, A. R. (1999): Autonomic innervation of human airways: structure, function, and pathophysiology in asthma, Neuroimmunomodulation, (vol. 6), No. 3, pp.145-59.

Voice, J. K.; Dorsam, G.; Chan, R. C.; Grinninger, C.; Kong, Y. and Goetzl, E. J. (2002): Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide, Regul Pept, (vol. 109), No. 1-3, pp.199-208.

Voice, J. K.; Dorsam, G.; Lee, H.; Kong, Y. and Goetzl, E. J. (2001): Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor, FASEB J, (vol. 15), No. 13, pp.2489-96.

von Euler, U. S. and Gaddum, J. H. (1931): An unidentified depressor substance in certain tissue extracts, J Physiol (Lond), (vol. 72), pp.74-87.

Wagner, U.; Bredenbroker, D.; Storm, B.; Tackenberg, B.; Fehmann, H. C. and von Wichert, P. (1998): Effects of VIP and related peptides on airway mucus secretion from isolated rat trachea, Peptides, (vol. 19), No. 2, pp.241-5.

Wallengren, J. (1997): Vasoactive peptides in the skin, J Investig Dermatol Symp Proc, (vol. 2), No. 1, pp.49-55.

Wang, H. Y.; Jiang, X. M. and Ganea, D. (2000): The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells, J Neuroimmunol, (vol. 104), No. 1, pp.68-78.


[Seite 74↓]

Webber, S. E. and Widdicombe, J. G. (1987): The effect of vasoactive intestinal peptide on smooth muscle tone and mucus secretion from the ferret trachea, Br J Pharmacol, (vol. 91), No. 1, pp.139-48.

Wei, Y. and Mojsov, S. (1996): Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology, J Neuroendocrinol, (vol. 8), No. 11, pp.811-7.

Widdicombe, J. G. (1998): Autonomic regulation. i-NANC/e-NANC, Am J Respir Crit Care Med, (vol. 158), No. 5 Pt 3, pp.S171-5.

Widdicombe, J. G. (2003): Overview of neural pathways in allergy and asthma, Pulm Pharmacol Ther, (vol. 16), No. 1, pp.23-30.

Xia, M.; Sreedharan, S. P.; Bolin, D. R.; Gaufo, G. O. and Goetzl, E. J. (1997): Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor, J Pharmacol Exp Ther, (vol. 281), No. 2, pp.629-33.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
25.11.2004